nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Alternating chemotherapy with VDC-IE as effective first-line treatment in a patient with SMARCA4-deficient undifferentiated tumor
|
Popov, Petar |
|
|
17 |
4 |
p. 307-309 |
artikel |
2 |
Can artificial intelligence provide accurate and reliable answers to cancer patients’ questions about cancer pain? Comparison of chatbots based on ESMO cancer pain guideline
|
Bir Yücel, Kadriye |
|
|
17 |
4 |
p. 302-306 |
artikel |
3 |
CAR-T cell therapy for relapsed or refractory multiple myeloma in 2024—clinically available treatment options in Austria
|
Strassl, Irene |
|
|
17 |
4 |
p. 242-246 |
artikel |
4 |
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
|
Suppan, Christoph |
|
|
17 |
4 |
p. 251-253 |
artikel |
5 |
GATA2 deficiency: a mystery myelodysplasia
|
Shoaib, Raqiya |
|
|
17 |
4 |
p. 315-321 |
artikel |
6 |
Impact of the WHO-5 classification of haematolymphoid tumours on clinical practice
|
Brand, Rosa |
|
|
17 |
4 |
p. 269-273 |
artikel |
7 |
Importance of genetic clarification in cytopenia syndromes (childhood myelodysplastic syndrome forms)
|
Novak, Wolfgang |
|
|
17 |
4 |
p. 297-301 |
artikel |
8 |
KRAS: Finally a druggable target in oncology?
|
Ilhan-Mutlu, Aysegul |
|
|
17 |
4 |
p. 239 |
artikel |
9 |
KRAS (Kirsten rat sarcoma) in modern oncology—The molecular pathological point of view
|
Schmitz, Katja |
|
|
17 |
4 |
p. 287-291 |
artikel |
10 |
NEC versus NET G3—is there a grey zone? Case report of pancreatic NET G3 with rapid disease progression
|
Melhorn, Philipp |
|
|
17 |
4 |
p. 310-314 |
artikel |
11 |
New therapy options for myelodysplastic syndrome—all for all or targeted?
|
Petzer, Verena |
|
|
17 |
4 |
p. 254-256 |
artikel |
12 |
Next generation of drugs in breast cancer
|
Bartsch, Rupert |
|
|
17 |
4 |
p. 280-286 |
artikel |
13 |
Not only a chicken and egg problem in children with pancytopenia
|
Dworzak, Michael N. |
|
|
17 |
4 |
p. 240-241 |
artikel |
14 |
Recent developments in marginal zone lymphoma
|
Raderer, Markus |
|
|
17 |
4 |
p. 247-250 |
artikel |
15 |
State-of-the-art therapy and innovative treatment strategies in esophageal squamous cell cancer
|
Korpan, Martin |
|
|
17 |
4 |
p. 274-279 |
artikel |
16 |
Treatment sequencing in gastroenteropancreatic neuroendocrine tumors
|
Melhorn, Philipp |
|
|
17 |
4 |
p. 257-262 |
artikel |
17 |
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
|
Doleschal, Bernhard |
|
|
17 |
4 |
p. 292-296 |
artikel |
18 |
Updates and changes in the treatment of cervical cancer
|
Danisch, M. |
|
|
17 |
4 |
p. 263-268 |
artikel |